Pacira BioSciences, Inc. (PCRX) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Pacira BioSciences, Inc. Do?
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. Pacira BioSciences, Inc. (PCRX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David M. Stack and employs approximately 720 people, headquartered in Parsippany, Florida. With a market capitalization of $923M, PCRX is one of the notable companies in the Healthcare sector.
Pacira BioSciences, Inc. (PCRX) Stock Rating — Hold (April 2026)
As of April 2026, Pacira BioSciences, Inc. receives a Hold rating with a composite score of 40.6/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.PCRX ranks #1,708 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Pacira BioSciences, Inc. ranks #167 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
PCRX Stock Price and 52-Week Range
Pacira BioSciences, Inc. (PCRX) currently trades at $23.79. The stock lost $0.03 (0.1%) in the most recent trading session. The 52-week high for PCRX is $27.64, which means the stock is currently trading -13.9% from its annual peak. The 52-week low is $18.80, putting the stock 26.5% above its annual trough. Recent trading volume was 249K shares, suggesting relatively thin trading activity.
Is PCRX Overvalued or Undervalued? — Valuation Analysis
Pacira BioSciences, Inc. (PCRX) carries a value factor score of 44/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 148.88x, compared to the Healthcare sector average of 23.63x — a premium of 530%. The price-to-book ratio stands at 1.32x, versus the sector average of 2.75x. The price-to-sales ratio is 1.31x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, PCRX trades at 16.73x EV/EBITDA, versus 6.34x for the sector.
Overall, PCRX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Pacira BioSciences, Inc. Profitability — ROE, Margins, and Quality Score
Pacira BioSciences, Inc. (PCRX) earns a quality factor score of 49/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -19.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -10.9% versus the sector average of -33.1%.
On a margin basis, Pacira BioSciences, Inc. reports gross margins of 78.7%, compared to 71.5% for the sector. The operating margin is -18.3% (sector: -66.1%). Net profit margin stands at -20.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 0.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
PCRX Debt, Balance Sheet, and Financial Health
Pacira BioSciences, Inc. has a debt-to-equity ratio of 54.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 4.54x, indicating strong short-term liquidity. Total debt on the balance sheet is $372M. Cash and equivalents stand at $148M.
PCRX has a beta of 0.30, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Pacira BioSciences, Inc. is 72/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
Pacira BioSciences, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Pacira BioSciences, Inc. reported revenue of $698M and earnings per share (EPS) of $0.16. Net income for the quarter was $-138M. Gross margin was 78.7%. Operating income came in at $-123M.
In FY 2025, Pacira BioSciences, Inc. reported revenue of $726M and earnings per share (EPS) of $0.16. Net income for the quarter was $7M. Gross margin was 79.4%. Revenue grew -48.2% year-over-year compared to FY 2024. Operating income came in at $19M.
In Q3 2025, Pacira BioSciences, Inc. reported revenue of $180M and earnings per share (EPS) of $0.12. Net income for the quarter was $5M. Gross margin was 80.9%. Revenue grew 6.5% year-over-year compared to Q3 2024. Operating income came in at $6M.
In Q2 2025, Pacira BioSciences, Inc. reported revenue of $181M and earnings per share (EPS) of $-0.11. Net income for the quarter was $-5M. Gross margin was 77.4%. Revenue grew 1.7% year-over-year compared to Q2 2024. Operating income came in at $8M.
Over the past 8 quarters, Pacira BioSciences, Inc. has demonstrated a growth trajectory, with revenue expanding from $178M to $698M. Investors analyzing PCRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
PCRX Dividend Yield and Income Analysis
Pacira BioSciences, Inc. (PCRX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
PCRX Momentum and Technical Analysis Profile
Pacira BioSciences, Inc. (PCRX) has a momentum factor score of 34/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 33/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
PCRX vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Pacira BioSciences, Inc. (PCRX) ranks #167 out of 838 stocks based on the Blank Capital composite score. This places PCRX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing PCRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PCRX vs S&P 500 (SPY) comparison to assess how Pacira BioSciences, Inc. stacks up against the broader market across all factor dimensions.
PCRX Next Earnings Date
No upcoming earnings date has been announced for Pacira BioSciences, Inc. (PCRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy PCRX? — Investment Thesis Summary
Pacira BioSciences, Inc. presents a balanced picture with arguments on both sides. Momentum is weak at 34/100, a headwind for near-term performance. Low volatility (stability score 72/100) reduces downside risk.
In summary, Pacira BioSciences, Inc. (PCRX) earns a Hold rating with a composite score of 40.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PCRX stock.
Related Resources for PCRX Investors
Explore more research and tools: PCRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PCRX head-to-head with peers: PCRX vs AZN, PCRX vs SLGL, PCRX vs VMD.